MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of 322 million yuan for the first half of the year, an increase of 2.45% year-on-year.

21:58 26/08/2026

MicroPort Scientific Corporation (00853) issued an announcement stating that its subsidiary, Shanghai MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech), achieved a revenue of 794 million yuan for the six months ending June 30, 2026, representing an increase of 11.13% year-on-year; the net profit attributable to the equity holders of CardioFlow Medtech was 322 million yuan, marking a year-on-year increase of 2.45%.

MICROPORT (00853) announced that its subsidiary Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. achieved revenue of 794 million RMB for the six months ending June 30, 2026, an increase of 11.13% year-on-year; the net profit attributable to shareholders of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. was 322 million RMB, an increase of 2.45% year-on-year.

FAR INTL (02516) released its interim results, with a profit attributable to shareholders of 4.922 million yuan, reversing the loss from the same period last year.

AI X TECH (01490) announced its interim results, with a net profit attributable to shareholders of 15.808 million yuan, turning a profit compared to the same period last year.

BIOSTAR PHARM-B (02563) announced its mid-term performance, reporting a net loss of 26.596 million yuan, a year-on-year reduction of 50.8%.

FAR INTL (02516) released its interim results, with a profit attributable to shareholders of 4.922 million yuan, reversing the loss from the same period last year.

AI X TECH (01490) announced its interim results, with a net profit attributable to shareholders of 15.808 million yuan, turning a profit compared to the same period last year.

BIOSTAR PHARM-B (02563) announced its mid-term performance, reporting a net loss of 26.596 million yuan, a year-on-year reduction of 50.8%.